Abstract—
Intranasal administration of lysine- and arginine-containing peptides Lys-Lys-Arg-Arg-Pro-Gly-Pro and Lys-Arg-Arg-Lys-Pro-Gly-Pro was performed daily at a single dose of 100 µg/kg for 7 days on laboratory rats with experimental metabolic syndrome and endothelial dysfunction. Metabolic syndrome was modeled by a high-calorie diet maintained throughout the experimental period, while endothelial dysfunction was simulated by daily intraperitoneal injection of L–NAME at a single dose of 10 mg/kg for 5 days. It was found that these peptides had anticlotting, hypoglycemic, and lipid-lowering effects and reduced body weight gain in experimental rats. They affected both primary (vascular-platelet) hemostasis, decreasing platelet aggregation, and all elements of plasma hemostasis by increasing anticoagulant, fibrin-depolymerizing, and enzymatic fibrinolytic activities as well as anti-fibrin-stabilizing properties of plasma and reducing the concentration of fibrinogen in it. At the same time, the studied peptides diminished the content of total cholesterol, low-density lipoprotein cholesterol, and triglycerides, while increasing the concentration of high-density lipoprotein cholesterol. These effects were observed 20 h after the last administration of peptides and persisted, although to a lesser extent, 7 days (168 h) after treatment withdrawal. In this regard, the prolonged action can be considered for both glyproline peptides containing lysine and arginine aminoacid residues in their structure and their ability to protect the body from the development of metabolic diseases and endothelial dysfunction. The maximum effects were provided by the Lys-Arg-Arg-Lys-Pro-Gly-Pro peptide, which may be associated with its structural features.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.3103%2FS009639252101003X/MediaObjects/11966_2021_2076_Fig1_HTML.gif)
Similar content being viewed by others
REFERENCES
McCracken, E., Monaghan, M., and Sreenivasan, S., Pathophysiology of the metabolic syndrome, Clin. Dermatol., 2018, vol. 36, no. 1, pp. 14–20.
Lee, S.K., Khambhati, J., Bhagava, A., Engels, M.C., Sandesara, P.B., and Quyyumi, A.A., Endothelial dysfunction and metabolic syndrome, Hypertens. J., 2017, vol. 3, no. 2, pp. 72–80.
Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R., Obesity induces a phenotypic switch in the polarization of adipose tissue macrophages, J. Clin. Invest., 2007, vol. 117, no. 1, pp. 175–184.
Brownlee, M., Pathobiology of diabetic complications: Unifying mechanism, Diabetes, 2005, vol. 54, no. 6, pp. 1615–1625.
Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., and Sai, Y., CCR5 plays an important role in obesity-induced adipose tissue inflammation and insulin resistance, regulating both macrophage recruitment and M1/M2 status, Diabetes, 2012, vol. 61, no. 7, pp. 1680–1690.
Forbes, J.M. and Cooper, M.E., Mechanisms of diabetic complications, Physiol. Rev., 2013, vol. 93, no. 1, pp. 137–188.
Beverly, J.K. and Budoff, M.J., Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation, J. Diabetes, 2020, vol. 12, no. 2, pp. 102–104.
Zhang, Z., Liu, J., Wang, H., Wu, H., Wu, X., Dong, J., and Liao, L., Association between a variant of the chemokine receptor 5 (CCR5) delta32 gene and atherosclerosis: Meta analysis of 13 studies, Int. J. Clin. Exp. Med., 2015, vol. 8, no. 1, pp. 658–665.
Pothineni, N.V.K., Subramany, S., Kuriakose, K., Shirazi, L.F., Romeo, F., Shah, P.K., and Mehta, J.L., Infections, atherosclerosis, and coronary heart disease, Eur. Heart J., 2017, vol. 38, no. 43, pp. 3195–3201.
Gresele, P. and Momi, S., Nitric oxide-enhancing or -releasing agents as antithrombotic drugs, Biochem. Pharmacol., 2019, vol. 166, pp. 300–312.
Kawano, H., Motoyama, T., Hirai, N., Kigiyama, K., Yasue, H., and Ogawa, H., Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: On possible role of oxidative stress, Atherosclerosis, 2002, vol. 161, no. 2, pp. 375–380.
Myasoedov, N.F., Lyapina, L.A., Andreeva, L.A., Grigorieva, M.E., Obergan, T.Y., and Shubina, T.A., The modern view on the role of glyprolines by metabolic syndrome, Med. Res. Rev., 2020. https://doi.org/10.1002/med.21748
Tian, D.L., Guo, R.J., Li, Y.M., Chen, P.P., Zi, B.B., Wang, J.J., Liu, R.F., Min, Y.N., Wang, Z.P., Niu, Z.Y., and Liu, F.Z., Effects of lysine deficiency or excess on growth and the expression of lipid metabolism genes in slow-growing broilers, Poultry Sci., 2019, vol. 98, no. 7, pp. 2927–2932.
Myasoedov, N.F., Lyapina, L.A., Grigorjeva, M.E., Obergan, T.Y., Shubina, T.A., and Andreeva, L.A., Mechanism for glyproline protection in hypercholesterolemia, Pathophysiology, 2016, vol. 23, no. 1, pp. 27–33.
Lyapina, L.A., Grigor’eva, M.E., Obergan, T.Yu., and Shubina, T.A., Teoreticheskie i prakticheskie voprosy izucheniya funktsional’nogo sostoyaniya protivosvertyvayushchei sistemy krovi (Theoretical and Practical Problems of Studying the Functional State of the Blood Anticoagulant System), Moscow: Advansed Solyushnz, 2012.
Yao, L., Herlea-Pana, O., Heuser-Baker, J., Chen, Y., and Barlic-Dicen, J., Roles of the chemokine system in the development of obesity, insulin resistance and cardiovascular disease, J. Immunol. Res., 2014, vol. 2014, artic. no. 181450.
Grandi, G. and Wolfrum, C., Hemostasis, endothelial stress, inflammation, and the metabolic syndrome, Semin. Immunopathol., 2018, vol. 40, no. 2, pp. 215–224.
Davel, A.P., Wenceslau, C.F., Akamine, E.H., Xavier, F.E., Couto, G.K., Oliveira, H.T., and Rossoni, L.V., Endothelial dysfunction in cardiovascular and endocrine-metabolic diseases: An update, Braz. J. Med. Biol. Res., 2011, vol. 44, no. 9, pp. 920–932.
Rask-Madsen, C. and King, G.L., Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes, Nat. Clin. Pract. Endocrinol. Metab., 2007, vol. 3, no. 1, pp. 46–56.
Li, G., Zhu, G., Gao, Y., **ao, W., Xu, H., and Liu, S., Neferin inhibits upregulation of CCL5 and CCR5 in vascular endothelial cells during chronic high glucose processing, Inflammation, 2013, vol. 36, no. 2, pp. 300–308.
Grigor'eva, M.E., Lyapina, L.A., and Obergan, T.Yu., Use of glyprolines for regulation of primary hemostasis and vascular-endothelial function of the body in the metabolic syndrome, Tromboz Gemostaz Reol., 2019, no. 3, pp. 32–37.
Kopincová, J., Púzserová, A., and Bernátová, I., L-NAME in the cardiovascular system – nitric oxide synthase activator?, Pharmacol. Rep., 2012, vol. 64, no. 3, pp. 511–520.
Grandl, G. and Wolfrum, C., Hemostasis, endothelial stress, inflammation, and the metabolic syndrome, Semin. Immunopathol., 2018, vol. 40, no. 2, pp. 215–224.
Lyapina, L.A., Myasoedov, N.F., Grigor’eva, M.E., Shubina, T.A., and Andreeva, L.A., The modern conception of the regulatory role of peptides of the glyproline family in the correction of hemostasis system function during development of diabetes mellitus, Biol. Bull., 2013, vol. 40, no. 2, pp. 381–393.
Grigor'eva, M.E., Lyapina, L.A., Shubina, T.A., Andreeva, L.A., Obergan, T.Yu., Pastorova, V.E., Myasoedov, N.F., and Ul’yanov, A.M., Protective effects of the Pro-Gly-Pro-Arg peptide in conditions of increased blood clotting in experimental hyperglycemia, Tromboz Gemostaz Reol., 2011, no. 3, pp. 41–46.
Shabalina, A.A., Kostyreva, M.V., Tanashyan, M.M., Susina, Z.A., Lyapina, L.A., and Rochev, D.L., In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood, Biol. Bull., 2015, vol. 42, no. 1, pp. 74–77.
Funding
The study was conducted within the “Physiological Regulators of Coagulative and Anticoagulative Systems in Normal and Pathological Conditions” State Task no. АААА–А16–16021660094–0 at the premises of the Institute of Molecular Genetics of Kurchatov National Research Center.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of interests. The authors declare that they have no conflicts of interests.
Statement on the welfare of animals. All experiments were conducted in accordance with the ethical principles of using laboratory animals and approved by the local ethical committee (Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia).
ADDITIONAL INFORMATION
Lyapina ORCID 0000-0002-8983-652X
Obergan ORCID 0000-0002-3760-3943
Grigorjeva ORCID 0000-0003-0469-3943
Shubina ORCID 0000-0003-1092-8382
Additional information
Translated by E. Sherstyuk
About this article
Cite this article
Myasoedov, N.F., Lyapina, L.A., Obergan, T.Y. et al. The Effects of KKRRPGP (Lys-Lys-Arg-Arg-Pro-Gly-Pro) and KRRKPGP (Lys-Arg-Arg-Lys-Pro-Gly-Pro) Peptides on Hemostasis Parameters, Lipid Profile, Blood Glucose Level, and Body Weight Changes in Rats with Metabolic Syndrome and Endothelial Dysfunction. Moscow Univ. Biol.Sci. Bull. 76, 7–13 (2021). https://doi.org/10.3103/S009639252101003X
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S009639252101003X